Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITE DE PARIS maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions, indicating ongoing interaction with the patent office. These actions are distributed across 2 distinct examiners, showing that the workload is not concentrated under a single individual.
The busiest examiner identified for this portfolio is QIAN, CELINE X, who is responsible for 1 pending office action. This means that QIAN, CELINE X handles a portion of the current pending workload. The remaining pending office action is managed by the other of the 2 distinct examiners involved in the portfolio's prosecution.
The prosecution activity spans 2 distinct art units. This distribution suggests that the Biotechnology & Pharmaceuticals innovations from UNIVERSITE DE PARIS cover diverse sub-sectors that fall under different administrative groups. Practitioners must navigate the specific procedural nuances of 2 different art units and the individual preferences of 2 separate examiners. The busiest examiner pending count of 1 is the same as the count for the other examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
| BEGEMAN, ANDREW W | 1 | 46.2% | +20.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246270 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | QIAN, CELINE X | 29d |
| 16970810 | METHOD AND APPARATUS FOR SIMULTANEOUS 4D ULTRAFAST BLOOD FLOW AND TISSUE DOPPLER IMAGING OF THE HEART AND RETRIEVING QUANTIFICATION PARAMETERS | BEGEMAN, ANDREW W | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 3798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246270 | BIFUNCTIONAL LENTIVIRAL VECTORS ALLOWING THE BS-GLOBIN SILENCING AND EXPRESSION OF AN ANTI-SICKLING HBB AND USES THEREOF FOR GENE THERAPY OF SICKLE CELL DISEASE | QIAN, CELINE X | 1637 | §103 | Final Rejection | 29d | Pending | Mar 22, 2023 |
| 16970810 | METHOD AND APPARATUS FOR SIMULTANEOUS 4D ULTRAFAST BLOOD FLOW AND TISSUE DOPPLER IMAGING OF THE HEART AND RETRIEVING QUANTIFICATION PARAMETERS | BEGEMAN, ANDREW W | 3798 | §103 | Non-Final OA | — | Pending | Aug 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial